Pharmacovigilance Specialist Nordics

Biomapas embarked on its journey in 2001, establishing its roots in Lithuania with a clear vision: to become a pivotal partner for the global life science industry. What began as a focused endeavor to provide clinical research services in the Baltics quickly evolved. By 2002, the company launched its Phase I-IV clinical research services, marking its formal entry into supporting drug development. The subsequent year, 2003, saw Biomapas conduct its first clinical trial in Belarus, signaling an early ambition for broader regional engagement. This expansion continued, and by 2004, Biomapas was already involved in clinical trials with biological and biosimilar products, showcasing its adaptability to the evolving pharmaceutical landscape.

The company's service portfolio broadened significantly in 2005 with the introduction of full-scope pharmacovigilance services, a critical component in ensuring drug safety post-market. Recognizing the increasing complexity of drug approval processes, Biomapas launched its regulatory affairs services in 2009, further solidifying its role as a comprehensive solutions provider. A commitment to quality and standardized processes was underscored in 2012 with the achievement of ISO 9001:2008 certification. Over the years, Biomapas has consistently expanded its geographical reach and service capabilities, now operating in over 60 countries across Europe, the CIS region, MENA, and EAEU. This growth has been driven by a dedication to combining global standards with local expertise, leveraging technology for efficiency, and fostering senior-level partnerships. Today, Biomapas stands as a functional and full outsourcing solution provider, offering expertise in clinical trials, regulatory affairs, pharmacovigilance, and medical information, always aiming to advance clinical development and ultimately improve patient health worldwide.